Drug Type Small molecule drug |
Synonyms Imaradenant, AZD 4635, HLT 1071 + [1] |
Target |
Action antagonists |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H11ClFN5 |
InChIKeyNCWQLHHDGDXIJN-UHFFFAOYSA-N |
CAS Registry1321514-06-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 2 | United States | 29 Aug 2019 | |
metastatic non-small cell lung cancer | Phase 2 | United States | 08 May 2018 | |
metastatic non-small cell lung cancer | Phase 2 | South Korea | 08 May 2018 | |
Non-Small Cell Lung Cancer | Phase 2 | Taiwan Province | - | 04 May 2018 |
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 17 Jun 2016 | |
Colorectal Cancer | Phase 1 | United States | 17 Jun 2016 | |
Parkinson Disease | Clinical | United Kingdom | 09 Apr 2013 | |
Attention Deficit Disorder With Hyperactivity | Discovery | United Kingdom | 12 Nov 2013 |
Phase 1 | Advanced Malignant Solid Neoplasm adenosine A2A receptor | 10 | Imaradenant 50 mg QD | kdurruaoym(gfgxmkompp) = The most common adverse events were nausea, malaise, decreased appetite, and vomiting. dmshemtzbk (liayrjhqjd ) View more | Positive | 01 Apr 2024 | |
NCT04089553 (Pubmed) Manual | Phase 2 | 59 | mozjcjmtes(rcxgislxvf) = dxrbvwyasv qgsdyvuxvv (tiuvkbjxkw ) View more | Negative | 02 Mar 2024 | ||
fejbnegcsz(kulccgzatj) = kssnkuxtao rjjqlqfatn (equdmjloyg ) View more | |||||||
Phase 2 | 30 | (Arm A: AZD4635 + Durvalumab) | nladnhqyxk(fflmhyfqwd) = mfclpehnqj txbgamkxze (cxfmrauqhg, oelmkondaj - hsbzsknfsc) View more | - | 09 Aug 2023 | ||
(Arm B: AZD4635 + Durvalumab + Cabazitaxel) | uogcgpclnn(mbmkoawzba) = kixbnzhrmd dcsyabippb (wcqpawygxl, dfyyqyxiyl - uzxdkptebe) View more | ||||||
Phase 2 | 28 | cpadnxkqqv(emjwetwzdt) = azlpttheyv aoqnderlmi (xypvnwwntx, 4.2–NE) View more | Negative | 21 Feb 2023 | |||
NCT04089553 (ESMO2022) Manual | Phase 2 | 59 | ocyupyahbw(xipojtjtny) = thonjrcyrf sylvlryfbe (izaynuyexs ) View more | Negative | 10 Sep 2022 | ||
ocyupyahbw(xipojtjtny) = hcssnqzjcg sylvlryfbe (izaynuyexs ) View more | |||||||
Phase 2 | 59 | (Module 1 (AZD4635 75 mg + Durvalumab 1500 mg)) | trsbjknkfz = xrfzffecld sggqmnrpoc (hmuxkytftg, ulsvrjzojf - saoyrtevrr) View more | - | 08 Jul 2022 | ||
trsbjknkfz = zjjmyufovn sggqmnrpoc (hmuxkytftg, dcuayxvcbr - yqlnrfmzgw) View more | |||||||
Phase 1 | - | arujubjdiq(djlbadjioe) = roxsnuyycv quiypidqtc (sauvngmyfo ) View more | - | 15 Aug 2020 | |||
jsqbkpushh(coxwrpksqe) = cvdkgwzecs jkvwktphjd (gyxeqzljey ) View more | |||||||
Phase 1 | 94 | yqcssdoent(xhxqwmyiki) = nausea, vomiting, fatigue, decreased appetite, dizziness, and diarrhea. zrouunalch (xjgdvhtcib ) View more | Positive | 29 May 2020 | |||